
Juneau Biosciences provides diagnostic testing services focused on women's health issues.
Juneau Biosciences, founded in Salt Lake City, UT, is dedicated to advancing women's health through innovative diagnostic testing services. The company's core mission is to address and improve the diagnosis and treatment of women's health issues, particularly focusing on disorders such as endometriosis and infertility. Juneau Biosciences offers specialized medical diagnostic services and actively engages in genetic research to develop more effective diagnostic tools and treatments.
Notable affiliated individuals include leading researchers and healthcare professionals in the field of women's health. The company has garnered support from key investors who are committed to advancing medical diagnostics. Juneau Biosciences has made significant strides in its research efforts, contributing valuable insights into the genetic factors of endometriosis and infertility. Their work has had a substantial impact on the medical community, offering new hope and improved care for women suffering from these conditions.

Juno Diagnostics
junodx.com

Cicero Diagnostics
cicerodx.com

Hera Biotech
herabiotech.com
Carmenta Bioscience
Gema Diagnostics
gemadx.com

Pediatric Bioscience

Exagen
exagen.com

DotLab
dotlab.com

GenQual
genqual.com

Myriad Genetics
myriad.com

Inherent Biosciences
inherentbio.com

Amplified Sciences

ID Genomics
idgenomics.com

Enable Biosciences

Sedia Biosciences
sediabio.com
DxNA

FYR Diagnostics
fyrdiagnostics.com

Nanopath
nanopathdx.com
EDP Biotech
edpbiotech.com

Quadrant Biosciences
Companies similar to Juneau Biosciences include Juno Diagnostics, Cicero Diagnostics, Hera Biotech and Carmenta Bioscience.
Juneau Biosciences was founded in 2006.
Juneau Biosciences' headquarters is located in Salt Lake City, UT, US.
Juneau Biosciences' most recent funding round was for $25k (USD) in December 2013.
As of Dec 4, 2013, Juneau Biosciences has disclosed funding of $7.9M (USD).
Juneau Biosciences has 17 employees as of Feb 4, 2024.